People | December 09, 2022
Lupin appoints Spiro Gavaris as President of U.S. Generics Business
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
This product is based on Osmotic Controlled Release Oral Delivery System technology
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Revenue from operations up 26% to Rs. 768 crores
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Subscribe To Our Newsletter & Stay Updated
